Bevacizumab (BEV)

• A Randomized Open-Label, Noninferiority, Phase 3, Multicenter, Controlled Trial to Compare Laparoscopic Surgery With Open Surgery for Symptomatic, Noncurable Stage IV Colorectal Cancer (JCOG1107)
• Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis
• New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening
• Bevacizumab-targeted porous casein-coated cobalt ferrite nanoparticles: A potent theranostic agent for sunitinib delivery, VEGF trapping, and MRI
• Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV-2 translational study
• Case report and review of the literature regarding management of primary uterine primitive neuroectodermal tumors (PNET)
• Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting
• Analysis of Esophageal Ulcers Using the Japanese Adverse Drug Event Report Database

Bevacizumab is a monoclonal antibody that inhibits angiogenesis by clearing circulating VEGF, resulting in a decline in the contrast-enhancing tumor, which does not always correlate with treatment response.

Bevacizumab, as antibodies, were applied to inhibit tumor angiogenesis by preventing activation of vascular endothelial growth factor receptor.

Bevacizumab, is sold under the trade name Avastin (Genentech/ Roche, South San Francisco, California).

Bevacizumab for glioblastoma

Bevacizumab for diffuse intrinsic pontine glioma

see Bevacizumab for meningioma

see Bevacizumab for neurofibromatosis type 2

Radiation induced necrosis in the brain has been treated using bevacizumab.

Perez-Torres et al. validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, they found that VEGF over-expression and radionecrosis developed simultaneously, which precludes preventative anti-VEGF treatment ¹⁾.

Combining VEGF blockade with inhibition of Angiopoietin 2 may potentially overcome resistance to bevacizumab therapy ²⁾.